Similar articles

• Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris.

  Green RS, Djogovic D, Howes D. Green RS, et al. CJEM. 2012 Sep;14(5):265-9. doi: 10.2310/8000.2012.120769. CJEM. 2012. PMID: 22967692 English, French. No abstract available.
• [Sepsis in the surgical setting: indication for activated C protein].

  Payen DM, Matéo J. Payen DM, et al. Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:40-2. Ann Fr Anesth Reanim. 2003. PMID: 15359942 French. No abstract available.
• [Treatment of severe sepsis and multiple organ failure with activated protein C].

  Strøm JJ. Strøm JJ. Ugeskr Laeger. 2004 Mar 8;166(11):995. Ugeskr Laeger. 2004. PMID: 15049233 Danish. No abstract available.
• Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.

  Levi M. Levi M. Crit Care Med. 2003 Mar;31(3):984-5. doi: 10.1097/01.CCM.0000055386.01914.0C. Crit Care Med. 2003. PMID: 12627023 Review. No abstract available.
• [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].

  Heslet L, Nielsen JD, Schierbeck J, Andersen JS. Heslet L, et al. Ugeskr Laeger. 2004 Mar 8;166(11):997-1002. Ugeskr Laeger. 2004. PMID: 15049234 Review. Danish. No abstract available.